DGX Quest Diagnostics Incorporated Common Stock
NYSE · Health Care · Auf SEC EDGAR ansehen ↗ Schließen Okt 6, 2026 10-K/10-Q Jul 23, 2026DGX Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
DGX Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
| Ex-Datum | Split | Typ |
|---|---|---|
| 21. Juni 2005 | 2-for-1 | Vorwärts |
| 1. Juni 2001 | 2-for-1 | Vorwärts |
Über Quest Diagnostics Incorporated Common Stock Unternehmensübersicht von Wikipedia
Quest Diagnostics Inc. ist ein US-amerikanisches Unternehmen im Bereich der klinischen Labordiagnostik und Gesundheitsinformation. Der Hauptsitz befindet sich in Secaucus (New Jersey). Nach Angaben der Nachrichtenagentur Reuters war Quest Diagnostics 2013 das größte Labortest-Unternehmen in den USA. 2024 betrug der Jahresumsatz etwa 9,87 Mrd. US-Dollar bei rund 55.000 Beschäftigten. Die Aktie des Unternehmens wird an der New Yorker Börse gehandelt und Quest Diagnostics ist ein Bestandteil des Leitindex S&P-500.
Geschichte
Das Unternehmen wurde 1967 von Dr. Paul A. Brown in New York City gegründet. Ursprünglich firmierte es unter dem Namen Metropolitan Pathology Laboratories (MetPath). 1982 übernahm der Glas- und Chemiekonzern Corning MetPath, das daraufhin als Corning Clinical Laboratories weitergeführt wurde. Ende 1996 spaltete Corning seine Labordienste (Corning Clinical Laboratories) in ein eigenständiges Unternehmen aus und nannte es Quest Diagnostics Incorporated. Quest Diagnostics wurde am 31. Dezember 1996 an die Corning-Aktionäre ausgegeben und daraufhin an der NYSE gelistet. Zu diesem Zeitpunkt beschäftigte Quest bereits rund 18.700 Mitarbeiter und erwirtschaftete 1995 einen Umsatz von etwa 1,6 Mrd. USD.
In den folgenden Jahren expandierte Quest Diagnostics vor allem durch Zukäufe. 2005 erwarb das Unternehmen LabOne (einen Anbieter von Drogentest- und Gesundheitsdiensten) für 930 Millionen USD. 2007 folgte die Übernahme von AmeriPath (einem nationalen Anbieter anatomisch-pathologischer und onkologischer Labordienstleistungen) für eine nicht genannte Kaufsumme. Weitere Übernahmen und Partnerschaften stärkten die Position von Quest als umfassender Labordienstleister. Im September 2018 verlegte Quest Diagnostics den Firmensitz von Madison (New Jersey) nach Secaucus (New Jersey), wo sich heute die Konzernzentrale befindet.
Tätigkeit
Quest Diagnostics betreibt ein landesweites Netzwerk diagnostischer Labore, Patientenentnahmestellen und Logistikdienste. Nach Unternehmensangaben umfasst dieses Netzwerk etwa 2.400 eigene Patientenservicezentren sowie insgesamt rund 8.000 Anlaufstellen für Proben (inklusive mobiler Blutentnahme-Services). In Dutzenden Laboren quer durch die USA werden pro Jahr Abermillionen von Untersuchungen durchgeführt. Insgesamt bietet Quest Diagnostics mehrere tausend unterschiedliche Laboruntersuchungen an – von einfachen Blutwerten über molekulargenetische und mikrobiologische Tests bis zu spezialisierten Analysen etwa in den Bereichen Frauenheilkunde, Onkologie oder Infektionskrankheiten.
Daneben erbringt Quest Diagnostics auch spezifische Serviceleistungen im Gesundheitswesen. So bietet das Unternehmen unter anderem Programme für betriebliche Gesundheitsvorsorge und Drogentests an, die von Arbeitgebern, Versicherungen und Behörden genutzt werden. Eigene Angaben zufolge werden jährlich etwa ein Drittel aller erwachsenen US-Bürger und rund die Hälfte aller US-Ärzte und Krankenhäuser durch Quest-Diagnostikdienste versorgt. In der COVID-19-Pandemie stellte Quest Diagnostics zusätzlich umfangreiche Testkapazitäten bereit – Berichten zufolge kam es dabei zeitweise zu Verzögerungen aufgrund der starken Nachfrage.
Kontroversen
Quest Diagnostics stellte im April 2009 einen Rekord auf, als es 302 Millionen Dollar an die Regierung zahlte, um einen Fall von Medicare-Betrug beizulegen, in dem dem Unternehmen vorgeworfen wurde, fehlerhafte medizinische Testkits verkauft zu haben. Es war die höchste Qui-Tam-Zahlung (Whistleblower), die jemals von einem medizinischen Labor für die Herstellung und den Vertrieb eines fehlerhaften Produkts geleistet wurde.
Im Mai 2011 zahlte Quest 241 Millionen Dollar an den Bundesstaat Kalifornien, um einen Fall nach dem False Claims Act beizulegen, in dem dem Unternehmen vorgeworfen wurde, Medi-Cal, das Medicaid-Programm des Bundesstaates, überhöhte Rechnungen gestellt und illegale Rückvergütungen als Anreiz für Gesundheitsdienstleister gezahlt zu haben, die Labore von Quest zu nutzen.
Quelle: Wikipedia, CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | DGX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | 24.25-Jahres-Durchschnitt ≈17.7 | ≈17.7 | 23.3 | Unterbewertet | |
| P/S (TTM) | 2.25-Jahres-Durchschnitt ≈1.7 | ≈1.7 | 1.3 | Überbewertet | |
| K/B (MRQ) | 3.35-Jahres-Durchschnitt ≈2.7 | ≈2.7 | 2.9 | Fairer Wert | |
| EV / EBITDA | 14.45-Jahres-Durchschnitt ≈11.0 | ≈11.0 | 11.4 | Fairer Wert | |
| Kurs / FCF (TTM) | 18.65-Jahres-Durchschnitt ≈14.9 | ≈14.9 | · | · | |
| Kurs / Cashflow (TTM) | 13.25-Jahres-Durchschnitt ≈10.8 | ≈10.8 | 9.8 | Fairer Wert | |
| EV / Revenue (EV / Umsatz) | 2.85-Jahres-Durchschnitt ≈2.2 | ≈2.2 | · | · | |
| EV / FCF | 22.55-Jahres-Durchschnitt ≈18.8 | ≈18.8 | · | · | |
| Kurs / Materieller Buchwert (MRQ) | 4.3 | · | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | DGX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Betriebsgewinnmarge (TTM) | 14.1%5-Jahres-Durchschnitt ≈15.6% | ≈15.6% | 8.3% | Spitzenklasse | |
| EBITDA-Marge (TTM) | 19.1%5-Jahres-Durchschnitt ≈20.2% | ≈20.2% | 8.8% | Spitzenklasse | |
| Vorgewinnmarge (TTM) | 12.1%5-Jahres-Durchschnitt ≈14.5% | ≈14.5% | 3.8% | Spitzenklasse | |
| Nettogewinnmarge (TTM) | 9.2%5-Jahres-Durchschnitt ≈11.0% | ≈11.0% | 5.1% | Spitzenklasse | |
| ROA (TTM) | 6.5%5-Jahres-Durchschnitt ≈8.0% | ≈8.0% | 4.0% | Spitzenklasse | |
| ROE (TTM) | 14.4%5-Jahres-Durchschnitt ≈17.4% | ≈17.4% | 12.5% | Im Einklang | |
| ROIC | 9.2%5-Jahres-Durchschnitt ≈11.0% | ≈11.0% | 9.2% | Im Einklang |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | DGX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital (MRQ) | 0.85-Jahres-Durchschnitt ≈0.8 | ≈0.8 | 0.4 | Hohe Verschuldung | |
| Liquiditätsgrad (MRQ) | 1.65-Jahres-Durchschnitt ≈1.2 | ≈1.2 | 1.4 | Starke Liquidität | |
| Quick Ratio | 0.85-Jahres-Durchschnitt ≈1.0 | ≈1.0 | 0.8 | Starke Liquidität | |
| Langfristige Schulden / Eigenkapital (MRQ) | 0.75-Jahres-Durchschnitt ≈0.7 | ≈0.7 | 0.7 | Hohe Verschuldung |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | DGX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 11.8%5-Jahres-Durchschnitt ≈3.6% | ≈3.6% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 3.7%5-Jahres-Durchschnitt ≈0.06% | ≈0.06% | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | 3.2% | · | · | · | |
| EPS YoY (EPS VjV) | 13.8%5-Jahres-Durchschnitt ≈2.0% | ≈2.0% | · | · | |
| Net Income YoY (Nettogewinn YoY) | 13.9%5-Jahres-Durchschnitt ≈-1.4% | ≈-1.4% | · | · | |
| EPS CAGR 3Y (EPS CAGR 3J) | 3.2%5-Jahres-Durchschnitt ≈-9.4% | ≈-9.4% | · | · | |
| EPS CAGR 5Y (EPS CAGR 5J) | -3.5% | · | · | · | |
| Net Income CAGR 3Y (Nettoergebnis CAGR 3J) | 1.6%5-Jahres-Durchschnitt ≈-12.8% | ≈-12.8% | · | · | |
| Net Income CAGR 5Y (Nettoergebnis CAGR 5J) | -7.1% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | DGX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.75-Jahres-Durchschnitt ≈0.7 | ≈0.7 | 1.2 | Schwach | |
| Inventory Turnover (Lagerumschlag) | 39.15-Jahres-Durchschnitt ≈33.9 | ≈33.9 | 15.6 | Spitzenklasse | |
| Receivables Turnover (Forderungsumschlag) | 8.15-Jahres-Durchschnitt ≈7.7 | ≈7.7 | 10.5 | Schwach | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$239.9K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Dividenden Rendite, Ausschüttungsquote, Dividendenhistorie, 5-Jahres-CAGR
| Ex-Datum | Betrag | Währung | Rendite |
|---|---|---|---|
| Jul 8, 2026 | $0,86 | USD | ≈1.6% |
| Apr 6, 2026 | $0,86 | USD | ≈1.6% |
| Jan 13, 2026 | $0,80 | USD | ≈1.8% |
| Okt 3, 2025 | $0,80 | USD | ≈1.8% |
| Jul 7, 2025 | $0,80 | USD | ≈1.8% |
| Apr 7, 2025 | $0,80 | USD | ≈1.9% |
| Jan 14, 2025 | $0,75 | USD | ≈2.0% |
| Okt 4, 2024 | $0,75 | USD | ≈2.0% |
| Jul 8, 2024 | $0,75 | USD | ≈2.1% |
| Apr 5, 2024 | $0,75 | USD | ≈2.2% |
| Jan 16, 2024 | $0,71 | USD | ≈2.1% |
| Okt 5, 2023 | $0,71 | USD | ≈2.3% |
| Jul 10, 2023 | $0,71 | USD | ≈2.0% |
| Apr 6, 2023 | $0,71 | USD | ≈1.9% |
| Jan 17, 2023 | $0,66 | USD | ≈1.8% |
| Okt 3, 2022 | $0,66 | USD | ≈2.1% |
| Jul 5, 2022 | $0,66 | USD | ≈1.9% |
| Apr 5, 2022 | $0,66 | USD | ≈1.9% |
| Jan 18, 2022 | $0,62 | USD | ≈1.8% |
| Okt 4, 2021 | $0,62 | USD | ≈1.7% |
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Jul 20, 2026 | $3.12 | $2.85 | 9.3% |
| 31. März 2026 | $2.50 | $2.37 | 5.5% | |
| 31. Dezember 2025 | $2.42 | $2.38 | 1.5% | |
| 30. September 2025 | $2.60 | $2.53 | 2.8% | |
| 30. Juni 2025 | $2.62 | $2.60 | 0.93% | |
| 31. März 2025 | $2.21 | $2.17 | 1.7% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Cost of Revenue | $7.37B | $6.63B | $6.20B | $6.45B | $6.58B | $5.80B | $5.04B | $4.93B | $4.72B | $4.62B | $4.66B | $4.64B | |
| Gross Profit | · | · | · | · | · | $3.63B | $2.69B | $2.60B | $2.68B | $2.90B | $2.84B | $2.80B | |
| SG&A Expense | $1.97B | $1.77B | $1.64B | $1.87B | $1.73B | $1.55B | $1.46B | $1.42B | $1.44B | $1.38B | $1.68B | $1.73B | |
| Operating Expenses | $9.48B | $8.53B | $7.99B | $8.46B | $8.41B | $7.47B | $6.50B | $6.43B | $6.24B | $5.94B | $6.09B | $6.45B | |
| Operating Income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B | $1.97B | $1.23B | $1.10B | $1.17B | $1.28B | $1.40B | $983M | |
| Interest Expense | · | · | $163M | $148M | $152M | $166M | $180M | $169M | $153M | $144M | $154M | $167M | |
| Interest Income | $13M | $25M | $11M | $10M | $1M | $3M | $5M | $2M | $2M | $1M | $1M | $3M | |
| Other Non-op | $26M | $30M | $20M | $-55M | $369M | $76M | $20M | $-8M | $16M | $-48M | $-143M | $4M | |
| Pretax Income | $1.32B | $1.18B | $1.13B | $1.24B | $2.60B | $1.88B | $1.08B | $926M | $1.03B | $1.09B | $1.10B | $823M | |
| Income Tax | $314M | $273M | $248M | $264M | $597M | $460M | $247M | $182M | $241M | $429M | $373M | $262M | |
| Net Income | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| EPS (Basic) | $8.87 | $7.78 | $7.59 | $8.10 | $15.85 | $10.62 | $6.36 | $5.39 | $5.63 | $4.58 | $4.92 | $3.83 | |
| EPS (Diluted) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 | $4.87 | $3.81 | |
| Shares (Basic) | 111,000,000 | 111,000,000 | 112,000,000 | 116,000,000 | 125,000,000 | 134,000,000 | 134,000,000 | 136,000,000 | 137,000,000 | 140,000,000 | 144,000,000 | 145,000,000 | |
| Shares (Diluted) | 113,000,000 | 113,000,000 | 113,000,000 | 118,000,000 | 128,000,000 | 136,000,000 | 136,000,000 | 139,000,000 | 140,000,000 | 142,000,000 | 145,000,000 | 145,000,000 | |
| EBITDA | $2.13B | $1.84B | $1.70B | $1.86B | $2.79B | $2.33B | $1.56B | $1.41B | $1.44B | $1.53B | $1.70B | $1.30B |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $420M | $549M | $686M | $315M | $872M | $1.16B | $1.19B | $135M | $137M | $359M | $133M | $192M | |
| Receivables | $1.41B | $1.30B | $1.21B | $1.20B | $1.44B | $1.52B | $1.06B | $1.01B | $924M | $926M | $901M | $932M | |
| Inventory | $189M | $188M | $190M | $192M | $208M | $223M | $123M | $99M | $95M | $82M | $84M | $110M | |
| Prepaid Expense | $361M | $351M | $286M | $196M | $223M | $157M | $112M | $144M | $150M | $155M | $207M | $186M | |
| Current Assets | $2.38B | $2.39B | $2.37B | $1.90B | $2.74B | $3.06B | $2.49B | $1.39B | $1.31B | $1.53B | $1.50B | $1.60B | |
| PP&E (Net) | $2.20B | $2.11B | $1.82B | $1.77B | $1.71B | $1.63B | $1.45B | $1.29B | $1.15B | $1.03B | $925M | $933M | |
| PP&E (Gross) | $6.18B | $5.77B | $5.23B | $5.10B | $4.79B | $4.62B | $4.23B | $3.97B | $3.67B | $3.43B | $3.23B | $3.13B | |
| Accum. Depreciation | $3.97B | $3.66B | $3.42B | $3.34B | $3.09B | $2.99B | $2.78B | $2.68B | $2.53B | $2.40B | $2.31B | $2.19B | |
| Goodwill | $8.95B | $8.86B | $7.73B | $7.22B | $7.09B | $6.87B | $6.62B | $6.56B | $6.33B | $6.00B | $5.91B | $6.03B | |
| Intangibles | $1.64B | $1.76B | $1.17B | $1.09B | $1.17B | $1.17B | $1.12B | $1.21B | $1.12B | $949M | $984M | $1.07B | |
| Other Non-current Assets | $270M | $255M | $198M | $144M | $163M | $176M | $160M | $119M | $136M | $148M | $174M | $172M | |
| Total Assets | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Accounts Payable | $1.60B | $1.39B | $1.36B | $1.40B | $1.60B | $1.63B | $1.04B | $1.02B | $1.02B | $975M | $1.01B | $1.19B | |
| Accrued Liabilities | $338M | $306M | $287M | $392M | $460M | $356M | $223M | $274M | $246M | $254M | $257M | $277M | |
| Current Liabilities | $2.28B | $2.17B | $1.81B | $1.55B | $1.75B | $1.78B | $1.99B | $1.49B | $1.06B | $981M | $1.17B | $1.71B | |
| Capital Leases | $537M | $535M | $503M | $489M | $494M | $499M | $413M | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $264M | $243M | $170M | $191M | $157M | $204M | |
| Other Non-current Liabilities | $957M | $938M | $876M | $812M | $792M | $847M | $711M | $745M | $663M | $654M | $514M | $594M | |
| Long-term Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.74B | |
| Total Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.76B | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Retained Earnings | $9.99B | $9.36B | $8.82B | $8.29B | $7.65B | $9.30B | $8.17B | $7.60B | $7.14B | $6.61B | $6.20B | $5.72B | |
| Treasury Stock | $5.18B | $4.86B | $4.83B | $4.67B | $3.45B | $5.37B | $5.22B | $5.00B | $4.78B | $4.46B | $3.96B | $3.81B | |
| AOCI | $-27M | $-88M | $-14M | $-21M | $-14M | $-21M | $-39M | $-59M | $-48M | $-72M | $-38M | $-27M | |
| Stockholders' Equity | $7.17B | $6.78B | $6.31B | $5.89B | $6.44B | $6.76B | $5.64B | $5.22B | $4.92B | $4.63B | $4.68B | $4.30B | |
| Liabilities + Equity | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 119,000,000 | 133,000,000 | 133,000,000 | 135,000,000 | 135,000,000 | 137,000,000 | 143,000,000 | 144,000,000 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $570M | $493M | $439M | $437M | $408M | $361M | $329M | $309M | $270M | $249M | $304M | $314M | |
| Stock-based Comp | $88M | $88M | $77M | $77M | $79M | $97M | $56M | $61M | $79M | $69M | $52M | $51M | |
| Deferred Tax | $105M | $13M | $-49M | $1M | $-57M | $85M | $15M | $73M | $9M | $37M | $112M | $23M | |
| Amort. of Intangibles | $154M | $127M | $108M | $120M | $103M | $103M | $96M | $90M | $74M | $72M | $81M | $94M | |
| Restructuring | · | · | · | $55M | $13M | $14M | $-3M | $49M | $30M | $11M | $39M | $43M | |
| Other Non-cash | $131M | $-131M | $-49M | $257M | $-192M | $31M | $-15M | $21M | $45M | $69M | $-367M | $-6M | |
| Operating Cash Flow | $1.89B | $1.33B | $1.27B | $1.72B | $2.23B | $2.00B | $1.24B | $1.20B | $1.18B | $1.12B | $821M | $944M | |
| CapEx | $527M | $425M | $408M | $404M | $403M | $418M | $400M | $383M | $252M | $293M | $263M | $308M | |
| Investing Cash Flow | $-631M | $-2.55B | $-1.06B | $-543M | $21M | $-772M | $-411M | $-801M | $-830M | $-127M | $-362M | $-1.02B | |
| Stock Repurchased | $450M | $151M | $275M | $1.41B | $2.20B | $325M | $353M | $322M | $465M | $590M | $224M | $132M | |
| Net Stock Activity | $-450M | $-151M | $-275M | $-1.41B | $-2.20B | $-325M | $-353M | $-322M | $-465M | $-590M | $-224M | $-132M | |
| Dividends Paid | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M | |
| Financing Cash Flow | $-1.39B | $1.08B | $160M | $-1.73B | $-2.54B | $-1.27B | $225M | $-401M | $-592M | $-738M | $-518M | $86M | |
| Net Change in Cash | $-129M | $-137M | $371M | $-557M | $-286M | · | · | · | $-222M | $226M | $-59M | $5M | |
| Taxes Paid | $169M | $256M | $317M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $1.36B | $909M | $864M | $1.31B | $1.83B | $1.59B | $843M | $817M | $923M | $776M | $547M | $630M | |
| Levered FCF | · | · | $737M | $1.20B | $1.71B | $1.46B | $704M | $681M | $806M | $689M | · | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 38.5% | 34.8% | 34.6% | 38.8% | 38.6% | 37.9% | 37.6% | |
| Operating Margin | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% | 20.9% | 15.9% | 14.6% | 15.1% | 17.0% | 18.7% | 13.2% | |
| Net Margin | 9.0% | 8.8% | 9.2% | 9.6% | 18.5% | 15.2% | 11.1% | 9.8% | 10.0% | 8.6% | 9.5% | 7.5% | |
| Pretax Margin | 11.9% | 11.9% | 12.2% | 12.5% | 24.1% | 20.0% | 13.9% | 12.3% | 13.4% | 14.4% | 14.7% | · | |
| EBITDA Margin | 19.3% | 18.6% | 18.4% | 18.9% | 25.9% | 24.7% | 20.2% | 18.7% | 18.6% | 20.3% | 22.7% | 17.4% | |
| ROA | 6.1% | 5.8% | 6.4% | 7.1% | 14.4% | 10.7% | 7.2% | 6.8% | 7.5% | 6.4% | 7.1% | 5.9% | |
| ROE | 14.2% | 13.3% | 14.0% | 15.3% | 30.2% | 23.1% | 15.8% | 14.5% | 16.2% | 13.9% | 15.8% | 13.5% | |
| ROIC | 9.2% | 8.0% | 8.9% | 11.4% | 17.5% | 13.8% | 9.1% | 9.7% | 10.2% | 9.2% | 11.1% | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 | 1.7 | 1.3 | 0.9 | 1.2 | 1.6 | 1.3 | 0.9 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 | 1.5 | 1.1 | 0.8 | 1.0 | 1.3 | 0.9 | 0.7 | |
| Debt / Equity | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 | 0.6 | 0.8 | 0.7 | 0.8 | 0.8 | 0.8 | 0.9 | |
| LT Debt / Equity | 0.7 | 0.8 | 0.7 | 0.7 | 0.6 | 0.6 | 0.7 | 0.7 | 0.8 | 0.8 | 0.7 | 0.8 | |
| Interest Coverage | · | · | 7.7 | 9.6 | 15.7 | 11.9 | 6.8 | 6.5 | 7.6 | 8.9 | · | · |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.8 | 0.8 | |
| Inventory Turnover | 39.1 | 35.1 | 32.5 | 32.2 | 30.5 | 33.5 | 45.4 | 50.8 | 53.3 | 55.6 | 48.0 | 46.1 | |
| Receivables Turnover | 8.1 | 7.9 | 7.7 | 7.5 | 7.3 | 7.3 | 7.4 | 7.8 | 8.3 | 8.2 | 8.2 | 8.3 |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $65.18 | $61.06 | $56.82 | $53.09 | $54.15 | $50.82 | $42.41 | $38.64 | $36.45 | $33.78 | $32.76 | $29.87 | |
| Revenue / Share | $97.65 | $87.36 | $81.88 | $83.75 | $84.28 | $69.39 | $56.81 | $54.18 | $55.06 | $52.92 | $51.68 | $51.28 | |
| Cash Flow / Share | $16.69 | $11.81 | $11.26 | $14.56 | $17.45 | $14.74 | $9.14 | $8.63 | $8.39 | $7.53 | $5.59 | $6.47 | |
| Cash / Share | $3.82 | $4.95 | $6.18 | $2.84 | $7.33 | $8.71 | $8.96 | $1.00 | $1.01 | $2.62 | $0.93 | $1.33 | |
| Dividend / Share | · | · | · | · | · | · | · | · | $1.80 | $1.65 | $1.52 | $1.32 | |
| EPS (TTM) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 | $4.87 | $3.81 |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.8% | 6.7% | -6.4% | -8.4% | 14.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 3.7% | -2.9% | -0.66% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 3.2% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 13.8% | 2.7% | -6.0% | -48.8% | 48.5% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 3.2% | -20.9% | -10.6% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -3.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 13.9% | 2.0% | -9.7% | -52.6% | 39.4% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 1.6% | -24.1% | -15.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -7.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 3.5% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Net Income TTM | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| Market Cap | $19.09B | $16.75B | $15.30B | $17.36B | $20.59B | $15.85B | $14.20B | $11.24B | $13.30B | $12.59B | $10.17B | $9.66B | |
| Enterprise Value | $24.34B | $22.41B | $19.33B | $21.03B | $23.73B | $18.71B | $17.78B | $15.00B | $16.94B | $15.97B | $13.69B | $13.23B | |
| P/E | 19.8 | 19.6 | 18.4 | 19.6 | 11.1 | 11.4 | 17.0 | 15.7 | 17.9 | 20.4 | 14.6 | 17.6 | |
| P/S | 1.7 | 1.7 | 1.7 | 1.8 | 1.9 | 1.7 | 1.8 | 1.5 | 1.8 | 1.7 | 1.4 | 1.3 | |
| P/B | 2.7 | 2.5 | 2.4 | 2.9 | 3.2 | 2.3 | 2.5 | 2.2 | 2.7 | 2.7 | 2.2 | 2.2 | |
| P / Cash Flow | 10.1 | 12.6 | 12.0 | 10.1 | 9.2 | 7.9 | 11.4 | 9.4 | 11.3 | 11.8 | 12.6 | 10.3 | |
| P / FCF | 14.0 | 18.4 | 17.7 | 13.2 | 11.3 | 10.0 | 16.8 | 13.8 | 14.4 | 16.2 | 18.6 | 15.3 | |
| EV / EBITDA | 11.4 | 12.2 | 11.4 | 11.3 | 8.5 | 8.0 | 11.4 | 10.6 | 11.8 | 10.5 | 8.0 | 10.2 | |
| EV / FCF | 17.9 | 24.7 | 22.4 | 16.0 | 13.0 | 11.8 | 21.1 | 18.4 | 18.4 | 20.6 | 25.0 | 21.0 | |
| EV / Revenue | 2.2 | 2.3 | 2.1 | 2.1 | 2.2 | 2.0 | 2.3 | 2.0 | 2.3 | 2.2 | 1.8 | 1.8 | |
| Dividend Yield | 1.8% | 2.0% | 2.1% | 1.8% | 1.5% | 1.9% | 2.0% | 2.4% | 1.9% | 1.8% | 2.1% | 1.9% | |
| Earnings Yield | 5.0% | 5.1% | 5.4% | 5.1% | 9.0% | 8.8% | 5.9% | 6.3% | 5.6% | 4.9% | 6.9% | 5.7% | |
| Payout Ratio | 35.6% | 38.0% | 36.8% | 32.2% | 15.5% | 20.8% | 33.3% | 36.1% | 32.0% | 34.6% | 29.9% | 33.6% | |
| Annual Payout | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.04B | $2.90B | $2.81B | $2.82B | $2.76B | $2.65B | $2.62B | $2.49B | $2.40B | $2.37B | $2.29B | $2.29B | $2.34B | $2.33B | $2.33B | $2.49B | |
| Cost of Revenue | $2.02B | $1.95B | $1.90B | $1.87B | $1.82B | $1.79B | $1.76B | $1.68B | $1.59B | $1.59B | $1.55B | $1.54B | $1.55B | $1.56B | $1.57B | $1.62B | |
| SG&A Expense | $529M | $504M | $504M | $501M | $486M | $476M | $466M | $448M | $416M | $440M | $407M | $380M | $416M | $439M | $563M | $464M | |
| Operating Expenses | $2.58B | $2.50B | $2.42B | $2.43B | $2.32B | $2.31B | $2.26B | $2.16B | $2.04B | $2.07B | $2.02B | $1.95B | $1.99B | $2.03B | $2.20B | $2.09B | |
| Operating Income | $459M | $399M | $386M | $386M | $438M | $346M | $361M | $330M | $355M | $300M | $267M | $342M | $348M | $305M | $135M | $392M | |
| Interest Expense | · | · | · | · | · | · | · | · | $47M | $49M | · | $41M | $39M | $37M | · | $37M | |
| Interest Income | $5M | $2M | $3M | $3M | $2M | $5M | $7M | $9M | $3M | $6M | $6M | $1M | $2M | $2M | $4M | $4M | |
| Other Non-op | $16M | $-2M | $8M | $8M | $13M | $-3M | $3M | $15M | $3M | $9M | $10M | $-3M | $6M | $7M | $6M | $-8M | |
| Pretax Income | $412M | $334M | $330M | $328M | $384M | $276M | $299M | $296M | $314M | $266M | $237M | $299M | $317M | $277M | $109M | $351M | |
| Income Tax | $88M | $74M | $81M | $77M | $97M | $59M | $68M | $65M | $74M | $66M | $40M | $68M | $75M | $65M | $-4M | $81M | |
| Net Income | $320M | $252M | $245M | $245M | $282M | $220M | $222M | $226M | $229M | $194M | $192M | $225M | $235M | $202M | $101M | $256M | |
| EPS (Basic) | $2.88 | $2.27 | $2.21 | $2.18 | $2.51 | $1.97 | $1.98 | $2.01 | $2.05 | $1.74 | $1.72 | $1.99 | $2.08 | $1.80 | $0.93 | $2.20 | |
| EPS (Diluted) | $2.84 | $2.24 | $2.18 | $2.16 | $2.47 | $1.94 | $1.95 | $1.99 | $2.03 | $1.72 | $1.70 | $1.96 | $2.05 | $1.78 | $0.92 | $2.17 | |
| Shares (Basic) | 111,000,000 | 110,000,000 | · | 112,000,000 | 112,000,000 | 111,000,000 | · | 112,000,000 | 111,000,000 | 111,000,000 | · | 112,000,000 | 112,000,000 | 112,000,000 | · | 116,000,000 | |
| Shares (Diluted) | 112,000,000 | 112,000,000 | · | 113,000,000 | 113,000,000 | 113,000,000 | · | 113,000,000 | 112,000,000 | 112,000,000 | · | 114,000,000 | 114,000,000 | 113,000,000 | · | 118,000,000 | |
| EBITDA | $605M | $546M | · | $528M | $581M | $486M | · | $455M | $472M | $416M | · | $453M | $460M | $412M | · | $500M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $626M | $393M | $420M | $432M | $319M | $188M | $549M | $764M | $271M | $474M | · | $143M | $126M | $175M | · | $700M | |
| Receivables | $1.67B | $1.59B | $1.41B | $1.46B | $1.42B | $1.40B | $1.30B | $1.38B | $1.32B | $1.32B | · | $1.28B | $1.24B | $1.25B | · | $1.28B | |
| Inventory | $233M | $225M | $189M | $186M | $187M | $189M | $188M | $184M | $182M | $181M | · | $184M | $184M | $190M | · | $183M | |
| Prepaid Expense | $319M | $361M | $361M | $333M | $273M | $294M | $351M | $299M | $245M | $251M | · | $207M | $188M | $195M | · | $171M | |
| Current Assets | $2.84B | $2.57B | $2.38B | $2.41B | $2.20B | $2.08B | $2.39B | $2.62B | $2.02B | $2.23B | · | $1.81B | $1.73B | $1.81B | · | $2.33B | |
| PP&E (Net) | $2.22B | $2.19B | $2.20B | $2.15B | $2.12B | $2.10B | $2.11B | $2.09B | $1.83B | $1.81B | · | $1.83B | $1.81B | $1.79B | · | $1.71B | |
| PP&E (Gross) | · | · | $6.18B | · | · | · | $5.77B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $3.97B | · | · | · | $3.66B | · | · | · | · | · | · | · | · | · | |
| Goodwill | $9.11B | $9.12B | $8.95B | $8.90B | $8.88B | $8.85B | $8.86B | $8.61B | $7.88B | $7.83B | $7.73B | $7.73B | $7.73B | $7.24B | $7.22B | $7.19B | |
| Intangibles | $1.67B | $1.72B | $1.64B | $1.66B | $1.71B | $1.73B | $1.76B | $1.72B | $1.20B | $1.19B | · | $1.22B | $1.25B | $1.08B | · | $1.11B | |
| Other Non-current Assets | $277M | $256M | $270M | $296M | $271M | $260M | $255M | $272M | $216M | $182M | · | $149M | $152M | $150M | · | $132M | |
| Total Assets | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Accounts Payable | $1.60B | $1.50B | $1.60B | $1.46B | $1.35B | $1.27B | $1.39B | $1.31B | $1.25B | $1.24B | · | $1.16B | $1.20B | $1.20B | · | $1.45B | |
| Accrued Liabilities | · | · | $338M | · | · | · | $306M | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $1.79B | $2.18B | $2.28B | $2.13B | $2.02B | $1.44B | $2.17B | $2.09B | $2.01B | $2.30B | · | $1.62B | $1.88B | $1.35B | · | $1.60B | |
| Capital Leases | $561M | $574M | $537M | $534M | $540M | $538M | $535M | $543M | $507M | $489M | · | $505M | $508M | $490M | · | $505M | |
| Other Non-current Liabilities | $1.06B | $1.02B | $957M | $982M | $890M | $917M | $938M | $891M | $811M | $817M | · | $874M | $901M | $809M | · | $787M | |
| Long-term Debt | $5.64B | · | $5.67B | · | · | · | $6.22B | $6.25B | · | · | · | · | · | · | · | · | |
| Total Debt | $5.64B | $503M | · | $504M | $504M | $1M | · | $6.25B | $606M | $906M | · | $304M | $518M | $2M | · | $2M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $10.37B | $10.15B | $9.99B | $9.84B | $9.68B | $9.49B | $9.36B | $9.22B | $9.08B | $8.94B | · | $8.71B | $8.57B | $8.41B | · | $8.26B | |
| Treasury Stock | $5.17B | $5.09B | $5.18B | $4.90B | $4.77B | $4.79B | $4.86B | $4.73B | $4.76B | $4.78B | · | $4.57B | $4.59B | $4.61B | · | $4.27B | |
| AOCI | $-62M | $-43M | $-27M | $-40M | $-16M | $-83M | $-88M | $-15M | $-19M | $-16M | · | $-20M | $-16M | $-18M | · | $-31M | |
| Stockholders' Equity | $7.52B | $7.37B | $7.17B | $7.26B | $7.23B | $6.93B | $6.78B | $6.81B | $6.62B | $6.43B | · | $6.42B | $6.25B | $6.05B | · | $6.24B | |
| Liabilities + Equity | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 110,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 114,000,000 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $146M | $147M | $145M | $142M | $143M | $140M | $135M | $125M | $117M | $116M | $109M | $111M | $112M | $107M | $116M | $108M | |
| Stock-based Comp | $23M | $20M | $25M | $20M | $21M | $22M | $27M | $19M | $20M | $22M | $19M | $18M | $16M | $24M | $22M | $18M | |
| Deferred Tax | $-2M | $48M | $-13M | $110M | $1M | $7M | $34M | $15M | $-18M | $-18M | $-10M | $-23M | $-12M | $-4M | $-44M | $65M | |
| Amort. of Intangibles | $38M | $37M | $37M | $39M | $39M | $39M | $37M | $32M | $29M | $29M | $27M | $27M | $28M | $26M | $39M | $27M | |
| Restructuring | · | · | · | $6M | $1M | · | · | $7M | $8M | · | · | $1M | $1M | · | · | · | |
| Other Non-cash | · | $-189M | · | · | · | $-75M | · | · | · | $-160M | · | · | · | $-235M | · | · | |
| Operating Cash Flow | $597M | $278M | $465M | $563M | $544M | $314M | $464M | $356M | $360M | $154M | $527M | $207M | $444M | $94M | $334M | $502M | |
| CapEx | $138M | $114M | $158M | $144M | $108M | $117M | $123M | $106M | $92M | $104M | $72M | $105M | $104M | $127M | $147M | $118M | |
| Investing Cash Flow | $-134M | $-152M | $-191M | $-201M | $-124M | $-115M | $-502M | $-1.63B | $-200M | $-213M | $-114M | $-107M | $-682M | $-158M | $-174M | $-118M | |
| Stock Repurchased | · | · | $300M | $150M | · | · | $151M | · | · | · | $275M | $0 | $0 | $0 | $461M | $374M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Dividends Paid | $96M | $88M | $90M | $89M | $90M | $84M | $84M | $84M | $84M | $79M | $80M | $80M | $80M | $74M | $75M | $78M | |
| Financing Cash Flow | $-229M | $-152M | $-287M | $-247M | $-293M | $-561M | $-170M | $1.77B | $-363M | $-153M | $130M | $-83M | $189M | $-76M | $-545M | $-474M | |
| Net Change in Cash | $233M | $-27M | $-12M | $113M | $131M | $-361M | $-215M | $493M | $-203M | $-212M | $543M | $17M | $-49M | $-140M | $-385M | $-90M | |
| Free Cash Flow | · | $164M | · | · | · | $197M | · | · | · | $50M | · | · | · | $-33M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $13M | · | · | · | $-61M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 15.1% | 13.8% | · | 13.7% | 15.9% | 13.1% | · | 13.3% | 14.8% | 12.7% | · | 14.9% | 14.9% | 13.1% | · | 15.8% | |
| Net Margin | 10.5% | 8.7% | · | 8.7% | 10.2% | 8.3% | · | 9.1% | 9.6% | 8.2% | · | 9.8% | 10.1% | 8.7% | · | 10.3% | |
| Pretax Margin | 13.5% | 11.5% | · | 11.7% | 13.9% | 10.4% | · | 11.9% | 13.1% | 11.2% | · | 13.0% | 13.6% | 11.9% | · | 14.1% | |
| EBITDA Margin | 19.9% | 18.9% | · | 18.8% | 21.0% | 18.3% | · | 18.3% | 19.7% | 17.6% | · | 19.7% | 19.7% | 17.7% | · | 20.1% | |
| ROA | 1.9% | 1.6% | · | 1.5% | 1.9% | 1.5% | · | 1.5% | 1.7% | 1.5% | · | 1.7% | 1.8% | 1.5% | · | 1.9% | |
| ROE | 4.3% | 3.5% | · | 3.5% | 4.1% | 3.3% | · | 3.4% | 3.6% | 3.1% | · | 3.5% | 3.7% | 3.2% | · | 4.0% | |
| ROIC | 2.7% | 4.0% | · | 3.8% | 4.2% | 3.9% | · | 2.0% | 3.8% | 3.1% | · | 3.9% | 3.9% | 3.9% | · | 4.8% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.2 | · | 1.1 | 1.1 | 1.4 | · | 1.3 | 1.0 | 1.0 | · | 1.1 | 0.9 | 1.3 | · | 1.5 | |
| Quick Ratio | 1.3 | 0.9 | · | 0.9 | 0.9 | 1.1 | · | 1.0 | 0.8 | 0.8 | · | 0.9 | 0.7 | 1.1 | · | 1.2 | |
| Debt / Equity | 0.8 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.9 | 0.1 | 0.1 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | |
| LT Debt / Equity | 0.7 | · | · | · | · | · | · | 0.8 | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 7.6 | 6.1 | · | 8.3 | 8.9 | 8.2 | · | 10.6 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 9.6 | 9.4 | · | 10.1 | 9.9 | 9.7 | · | 9.1 | 8.7 | 8.6 | · | 8.4 | 8.3 | 8.1 | · | 8.3 | |
| Receivables Turnover | 2.0 | 1.9 | · | 2.0 | 2.0 | 1.9 | · | 1.9 | 1.9 | 1.8 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $68.33 | $66.36 | · | $65.39 | $64.54 | $61.87 | · | $60.79 | $59.61 | $57.95 | · | $57.37 | $55.79 | $54.02 | · | $54.69 | |
| Revenue / Share | $27.17 | $25.85 | · | $24.92 | $24.43 | $23.47 | · | $22.02 | $21.40 | $21.12 | · | $20.13 | $20.51 | $20.63 | · | $21.07 | |
| Cash Flow / Share | · | $2.48 | · | · | · | $2.78 | · | · | · | $1.38 | · | · | · | $0.83 | · | · | |
| Cash / Share | $5.69 | $3.54 | · | $3.89 | $2.85 | $1.68 | · | $6.82 | $2.44 | $4.27 | · | $1.28 | $1.12 | $1.56 | · | $6.14 | |
| Dividend / Share | $0.86 | $0.86 | $0.80 | $0.80 | $0.80 | $0.80 | $0.75 | $0.75 | $0.75 | $0.75 | $0.71 | $0.71 | $0.71 | $0.71 | $0.66 | $0.66 | |
| EPS (TTM) | $9.42 | $9.05 | · | $8.52 | $8.35 | $7.91 | · | $7.44 | $7.41 | $7.43 | · | $6.71 | $6.92 | $6.83 | · | $10.16 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.56B | $11.28B | · | $10.85B | $10.52B | $10.16B | · | $9.54B | $9.35B | $9.29B | · | $9.30B | $9.49B | $9.60B | · | $10.29B | |
| Net Income TTM | $1.06B | $1.02B | · | $969M | $950M | $897M | · | $841M | $840M | $846M | · | $763M | $794M | $793M | · | $1.24B | |
| Market Cap | $23.31B | $21.75B | · | $21.15B | $20.12B | $18.95B | · | $17.39B | $15.19B | $14.78B | · | $13.65B | $15.74B | $15.85B | · | $13.99B | |
| Enterprise Value | $28.33B | $21.86B | · | $21.23B | $20.30B | $18.76B | · | $22.88B | $15.53B | $15.21B | · | $13.81B | $16.13B | $15.67B | · | $13.29B | |
| P/E | 22.5 | 21.7 | · | 22.4 | 21.5 | 21.4 | · | 20.9 | 18.5 | 17.9 | · | 18.2 | 20.3 | 20.7 | · | 12.1 | |
| P/S | 2.0 | 1.9 | · | 1.9 | 1.9 | 1.9 | · | 1.8 | 1.6 | 1.6 | · | 1.5 | 1.7 | 1.7 | · | 1.4 | |
| P/B | 3.1 | 3.0 | · | 2.9 | 2.8 | 2.7 | · | 2.6 | 2.3 | 2.3 | · | 2.1 | 2.5 | 2.6 | · | 2.2 | |
| P / Cash Flow | · | 78.3 | · | · | · | 60.4 | · | · | · | 95.9 | · | · | · | 168.6 | · | · | |
| EV / Revenue | 2.5 | 1.9 | · | 2.0 | 1.9 | 1.8 | · | 2.4 | 1.7 | 1.6 | · | 1.5 | 1.7 | 1.6 | · | 1.3 | |
| Dividend Yield | 1.6% | 1.6% | · | 1.6% | 1.7% | 1.8% | · | 1.9% | 2.1% | 2.2% | · | 2.3% | 1.9% | 1.9% | · | 2.2% | |
| Earnings Yield | 4.4% | 4.6% | · | 4.5% | 4.7% | 4.7% | · | 4.8% | 5.4% | 5.6% | · | 5.5% | 4.9% | 4.8% | · | 8.3% | |
| Payout Ratio | · | 34.9% | · | · | · | 38.2% | · | · | · | 40.7% | · | · | · | 36.6% | · | · | |
| Annual Payout | $363M | $357M | · | $347M | $342M | $336M | · | $327M | $323M | $319M | · | $309M | $307M | $305M | · | $307M |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B |
| Betriebsgewinnmarge % | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% |
| Nettoergebnis | $992M | $871M | $854M | $946M | $2.00B |
| Verwässerte EPS | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 |
| Liquiditätsgrad | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $1.36B | $909M | $864M | $1.31B | $1.83B |
Institutionelle Eigentümer (13F) 1.170 Einreicher · $23.2B gesamt · Stand 30. September 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 118 (-23 vs. Vorquartal) | 64 (-18 vs. Vorquartal) | 430 (+89 vs. Vorquartal) | 343 (-26 vs. Vorquartal) | +3.8M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| VANGUARD GROUP INC | $2.497.458.052 | 14.392.082 | 10,79% | Aktien |
| BlackRock, Inc. | $1.965.923.399 | 9.275.411 | 8,49% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.533.117.858 | 7.233.394 | 6,62% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.299.474.988 | 6.131.045 | 5,61% | Aktien |
| STATE STREET CORP | $1.169.252.484 | 5.516.643 | 5,05% | Aktien |
| Boston Partners | $1.004.552.880 | 4.744.473 | 4,34% | Aktien |
| JPMORGAN CHASE & CO | $748.586.197 | 3.520.438 | 3,23% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $662.582.607 | 3.137.873 | 2,86% | Aktien |
| MORGAN STANLEY | $521.503.271 | 2.460.497 | 2,25% | Aktien |
| EdgePoint Investment Group Inc. | $476.372.038 | 2.247.568 | 2,06% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $421.376.156 | 1.988.048 | 1,82% | Aktien |
| BANK OF AMERICA CORP /DE/ | $410.151.497 | 1.935.133 | 1,77% | Aktien |
| Grantham, Mayo, Van Otterloo & Co. LLC | $400.206.122 | 1.888.207 | 1,73% | Aktien |
| WELLS FARGO & COMPANY/MN | $371.171.119 | 1.751.220 | 1,60% | Aktien |
| Davis Selected Advisers | $329.781.509 | 1.555.612 | 1,42% | Aktien |
| VICTORY CAPITAL MANAGEMENT INC | $311.037.928 | 1.467.506 | 1,34% | Aktien |
| NORGES BANK | $298.133.109 | 1.406.620 | 1,29% | Aktien |
| FMR LLC | $296.462.102 | 1.398.735 | 1,28% | Aktien |
| Invesco Ltd. | $292.303.423 | 1.379.115 | 1,26% | Aktien |
| NORTHERN TRUST CORP | $238.963.873 | 1.127.454 | 1,03% | Aktien |
| GOLDMAN SACHS GROUP INC | $208.282.052 | 982.694 | 0,90% | Aktien |
| UBS Group AG | $188.403.627 | 888.906 | 0,81% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $173.422.135 | 818.220 | 0,75% | Aktien |
| M&G PLC | $168.677.800 | 795.650 | 0,73% | Aktien |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $165.917.256 | 846.603 | 0,72% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $163.988.047 | 773.711 | 0,71% | Aktien |
| AMERIPRISE FINANCIAL INC | $161.076.730 | 759.975 | 0,70% | Aktien |
| Legal & General Group Plc | $151.986.161 | 717.085 | 0,66% | Aktien |
| Bank of New York Mellon Corp | $133.388.337 | 629.339 | 0,58% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $131.756.386 | 621.639 | 0,57% | Aktien |
| DEUTSCHE BANK AG\ | $124.180.445 | 585.895 | 0,54% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $122.662.706 | 625.894 | 0,53% | Aktien |
| Nuveen, LLC | $119.503.667 | 563.830 | 0,52% | Aktien |
| PRINCIPAL FINANCIAL GROUP INC | $109.630.811 | 517.225 | 0,47% | Aktien |
| RAYMOND JAMES FINANCIAL INC | $107.196.222 | 505.762 | 0,46% | Aktien |
| Amundi | $105.710.274 | 498.751 | 0,46% | Aktien |
| Woodline Partners LP | $102.974.000 | 485.841 | 0,44% | Aktien |
| FIDUCIARY MANAGEMENT INC /WI/ | $102.489.906 | 483.557 | 0,44% | Aktien |
| Artemis Investment Management LLP | $99.175.856 | 467.921 | 0,43% | Aktien |
| CRAWFORD INVESTMENT COUNSEL INC | $97.514.204 | 460.081 | 0,42% | Aktien |
| BARCLAYS PLC | $95.107.474 | 448.726 | 0,41% | Aktien |
| ENVESTNET ASSET MANAGEMENT INC | $90.834.224 | 428.564 | 0,39% | Aktien |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $88.822.918 | 417.715 | 0,38% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $83.772.178 | 395.245 | 0,36% | Aktien |
| M.D. Sass, LLC | $76.397.960 | 360.453 | 0,33% | Aktien |
| Qube Research & Technologies Ltd | $72.783.206 | 343.398 | 0,31% | Aktien |
| MACKENZIE FINANCIAL CORP | $70.641.875 | 333.295 | 0,31% | Aktien |
| Advisors Capital Management, LLC | $69.429.626 | 327.575 | 0,30% | Aktien |
| CITIGROUP INC | $66.888.058 | 315.584 | 0,29% | Aktien |
| Swiss National Bank | $65.683.305 | 309.900 | 0,28% | Aktien |
Aktivisten & 5%+-Eigentümer 13 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated | 18. Mai 2011 | · | Erste Einreichung | M&A / Verkauf | SEC |
| Nicht offengelegter meldender Beteiligter | 1. Februar 2011 | · | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter | 20. März 2009 | · | Erste Einreichung | · | SEC |
| GlaxoSmithKline plc ×2 Einreichungen | 18. September 2008 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter | 16. Februar 2007 | · | Erste Einreichung | · | SEC |
| Quest Diagnostics Incorporated - (FEIN No. ×2 Einreichungen | 19. Januar 2006 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter | 15. Dezember 2004 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter | 29. Juni 2004 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter | 24. Juni 2002 | · | Erste Einreichung | M&A / Verkauf | SEC |
| Nicht offengelegter meldender Beteiligter | 22. Mai 2002 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter | 12. April 2002 | · | Erste Einreichung | M&A / Verkauf | SEC |
| IRS Identification Nos. of Above Persons (entities only) Quest Diagnostics Ventures LLC - (FEIN No., Quest Diagnostics Incorporated - (FEIN No. ×3 Einreichungen | 1. November 2001 | · | Erste Einreichung | M&A / Verkauf | SEC |
| Nicht offengelegter meldender Beteiligter | 14. Mai 2001 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 52 Insider · 26 Führungskräfte · 26 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| E. J. Davis | CEO and President | 1. September 2026 S | 122.423 | 0 | 6 | $-17.083.502 |
| Surya N Mohapatra | Chairman, President & CEO | 30. April 2012 F | 243.713 | 0 | 0 | $0 |
| Sam Samad | Executive Vice President & CFO | 22. Juli 2026 A | 33.478 | 0 | 0 | $0 |
| Mark Guinan | Executive Vice President & CFO | 7. März 2022 F | 98.981 | 0 | 0 | $0 |
| Robert Hagemann | SVP & Chief Financial Officer | 5. März 2013 F | 126.722 | 0 | 0 | $0 |
| Michael E Prevoznik | SVP & General Counsel | 28. August 2026 M | 36.557 | 0 | 6 | $-6.649.682 |
| Mark E Delaney | SVP & Chief Commercial Officer | 28. Juli 2026 S | 10.335 | 0 | 2 | $-1.864.971 |
| Karthik Kuppusamy | SVP, Clinical Solutions | 22. Juli 2026 L | 13.557 | 0 | 2 | $-2.167.772 |
| Patrick Plewman | SVP for Diagnostic Services | 22. Juli 2026 L | 15.293 | 0 | 4 | $-2.025.174 |
| Catherine T. Doherty | EVP, Regional Businesses | 5. März 2026 S | 67.122 | 0 | 8 | $-6.964.749 |
| Michael J Deppe | SVP, Corp. Controller & CAO | 4. März 2026 F | 35.196 | 0 | 0 | $0 |
| Mark A Gardner | SVP of Molecular Gen & Oncol | 24. September 2024 F | 4.673 | 0 | 0 | $0 |
| Manner Carrie Eglinton | SVP, Advanced Diagnostics | 7. März 2022 F | 48.391 | 0 | 0 | $0 |
| Manuel O. Mendez | SVP & Chief Commercial Officer | 17. Februar 2021 A | 29.045 | 0 | 0 | $0 |
| Robert A Klug | VP, Corporate Controller | 1. März 2019 F | 6.261 | 0 | 0 | $0 |
| Jon R Cohen | SVP & Group Exec. Diag. Sol. | 8. März 2018 M | 31.757 | 0 | 0 | $0 |
| Everett Cunningham | SVP, Commercial | 1. März 2018 G | 37.760 | 0 | 0 | $0 |
| Thomas F Bongiorno | VP and Corporate Controller | 2. März 2015 F | 11.837 | 0 | 0 | $0 |
| John B. Haydon | SVP, Operations | 13. Februar 2014 A | 19.890 | 0 | 0 | $0 |
| Kathy Ordonez | SVP, Diagnostic Solutions | 31. März 2013 F | 9.569 | 0 | 0 | $0 |
| Joan Elizabeth Miller | SVP-Oncology & Neurology Srvcs | 29. Februar 2012 F | 89.232 | 0 | 0 | $0 |
| Wayne R. Simmons | Vice President, Operations | 16. Juni 2011 M | 47.150 | 0 | 0 | $0 |
| Robert E Peters | VP, Sales & Marketing | 12. Februar 2007 A | 12.974 | 0 | 0 | $0 |
| David M Zewe | SVP, Diagnostic Testing Ops | 12. Februar 2007 A | 31.079 | 0 | 0 | $0 |
| GRANT THOMAS W II | Sr VP, Ins. & Employer Serv. | 12. Februar 2007 A | · | 0 | 0 | $0 |
| Gerald C Marrone | SVP, Administration | 28. Februar 2004 F | 49.609 | 0 | 0 | $0 |
| Timothy C Wentworth | Direktor | 1. Oktober 2026 A | 1.358 | 0 | 0 | $0 |
| Wright Lassiter III | Direktor | 22. Juli 2026 L | 10.323 | 0 | 0 | $0 |
| Vicky B Gregg | Direktor | 22. Juli 2026 A | 18.386 | 0 | 1 | $-239.700 |
| Robert B Carter | Direktor | 22. Juli 2026 L | 3.864 | 0 | 0 | $0 |
| Timothy L Main | Direktor | 22. Juli 2026 L | 22.460 | 0 | 0 | $0 |
| Luis Diaz | Direktor | 20. Mai 2026 A | 5.196 | 0 | 0 | $0 |
| Tracey Doi | Direktor | 20. Mai 2026 A | 7.748 | 0 | 0 | $0 |
| Timothy M Ring | Direktor | 20. Mai 2026 A | 31.140 | 0 | 0 | $0 |
| Gary M Pfeiffer | Direktor | 20. Mai 2026 A | 31.005 | 0 | 1 | $-270.317 |
| Gail R Wilensky | Direktor | 17. Mai 2023 A | 20.506 | 0 | 0 | $0 |
| Stephen H Rusckowski | Direktor | 6. März 2023 F | 389.597 | 0 | 0 | $0 |
| Helen Torley | Direktor | 25. Mai 2021 A | 6.260 | 0 | 0 | $0 |
| Daniel Stanzione | Direktor | 23. November 2020 S | 28.349 | 0 | 0 | $0 |
| Jenne K Britell | Direktor | 4. Juni 2018 G | 14.479 | 0 | 0 | $0 |
| Jeffrey M Leiden | Direktor | 29. Mai 2018 S | 6.000 | 0 | 0 | $0 |
| John B Ziegler | Direktor | 22. Februar 2017 S | 16.557 | 0 | 0 | $0 |
| John C Baldwin MD | Direktor | 12. August 2015 S | 12.949 | 0 | 0 | $0 |
| William F Buehler | Direktor | 12. Februar 2014 M | 26.225 | 0 | 0 | $0 |
| GSK plc | Direktor | 31. Januar 2011 S | 0 | 0 | 0 | $0 |
| Rosanne Haggerty | Direktor | 6. Mai 2010 A | 9.334 | 0 | 0 | $0 |
| William R Grant | Direktor | 1. April 2007 A | 3.334 | 0 | 0 | $0 |
| James F Flaherty III | Direktor | 4. Mai 2006 A | 1.667 | 0 | 0 | $0 |
| Kenneth D Brody | Direktor | 28. April 2004 S | 0 | 0 | 0 | $0 |
| Mary A Cirillo | Direktor | 1. April 2004 A | 2.627 | 0 | 0 | $0 |
| Denise M Morrison | · | 20. Mai 2026 A | 11.929 | 0 | 0 | $0 |
| FREEMAN KENNETH W/NJ | · | 14. Dezember 2004 F | 216.187 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 133 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| IHF · iShares Trust | 3,75% | 212.725 SH | 11. September 2026 | Täglich |
| RW · EA Series Trust | 2,50% | 1.865 NS | 31. Juli 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,64% | 61.314 SH | 5. Oktober 2026 | Täglich |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,49% | 67.178 NS | 31. Juli 2026 | N-PORT |
| CZA · Invesco Exchange-Traded Fund Trust | 1,28% | 11.113 SH | 5. Oktober 2026 | Täglich |
| NUDV · Nushares ETF Trust | 1,09% | 2.338 NS | 31. Juli 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,97% | 637 NS | 31. Juli 2026 | N-PORT |
| SPLV · Invesco Exchange-Traded Fund Trust … | 0,88% | 262.758 SH | 5. Oktober 2026 | Täglich |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,79% | 4.469 SH | 5. Oktober 2026 | Täglich |
| JOET · Virtus ETF Trust II | 0,78% | 8.139 NS | 31. Juli 2026 | N-PORT |
| ESMV · iShares Trust | 0,70% | 236 SH | 11. September 2026 | Täglich |
| QLV · FlexShares Trust | 0,63% | 4.452 NS | 31. Juli 2026 | N-PORT |
| HUSV · First Trust Exchange-Traded Fund III | 0,60% | 1.903 NS | 31. Juli 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0,46% | 369.448 NS | 31. Juli 2026 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,43% | 8.600 NS | 31. Juli 2026 | N-PORT |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,43% | 8.453 NS | 31. Juli 2026 | N-PORT |
| IYH · iShares Trust | 0,41% | 64.629 SH | 11. September 2026 | Täglich |
| VOE · VANGUARD INDEX FUNDS | 0,40% | 711.079 SH | 19. August 2026 | Täglich |
| FTA · First Trust Exchange-Traded AlphaDE… | 0,38% | 22.688 NS | 31. Juli 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,37% | 52.313 NS | 31. Juli 2026 | N-PORT |
| IMCV · iShares Trust | 0,36% | 18.030 SH | 11. September 2026 | Täglich |
| SUSA · iShares Trust | 0,34% | 59.240 SH | 11. September 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,34% | 330.273 SH | 19. August 2026 | Täglich |
| IXJ · iShares Trust | 0,32% | 58.047 SH | 11. September 2026 | Täglich |
| DFLV · Dimensional ETF Trust | 0,30% | 87.905 NS | 31. Juli 2026 | N-PORT |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,30% | 19.944 NS | 31. Juli 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,30% | 2.178 NS | 31. Juli 2026 | N-PORT |
| EQIN · Columbia ETF Trust I | 0,27% | 3.540 NS | 31. Juli 2026 | N-PORT |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0,26% | 9.337 NS | 31. Juli 2026 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0,26% | 27.542 NS | 31. Juli 2026 | N-PORT |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,25% | 7.574.000 | 5. Oktober 2026 | Täglich |
| IWS · iShares Trust | 0,25% | 165.299 SH | 11. September 2026 | Täglich |
| ESUM · Strategy Shares | 0,24% | 1.901 NS | 31. Juli 2026 | N-PORT |
| SIZE · iShares Trust | 0,24% | 4.359 SH | 11. September 2026 | Täglich |
| VO · VANGUARD INDEX FUNDS | 0,23% | 2.398.948 SH | 19. August 2026 | Täglich |
| VFMV · VANGUARD WELLINGTON FUND | 0,22% | 4.307 SH | 19. August 2026 | Täglich |
| RSP · Invesco Exchange-Traded Fund Trust | 0,20% | 827.048 SH | 5. Oktober 2026 | Täglich |
| ACWV · iShares, Inc. | 0,20% | 28.973 SH | 11. September 2026 | Täglich |
| EUSA · iShares, Inc. | 0,19% | 16.140 SH | 11. September 2026 | Täglich |
| FAB · First Trust Exchange-Traded AlphaDE… | 0,19% | 1.371 NS | 31. Juli 2026 | N-PORT |
| IWR · iShares Trust | 0,19% | 452.857 SH | 11. September 2026 | Täglich |
| IMCB · iShares Trust | 0,18% | 12.959 SH | 11. September 2026 | Täglich |
| MTUM · iShares Trust | 0,16% | 168.369 SH | 11. September 2026 | Täglich |
| DFVX · Dimensional ETF Trust | 0,16% | 3.609 NS | 31. Juli 2026 | N-PORT |
| DFUV · Dimensional ETF Trust | 0,15% | 97.399 NS | 31. Juli 2026 | N-PORT |
| ESLG · Strategy Shares | 0,15% | 146 NS | 31. Juli 2026 | N-PORT |
| XOEF · iShares Trust | 0,15% | 140 SH | 11. September 2026 | Täglich |
| CATH · Global X Funds | 0,12% | 6.867 NS | 31. Juli 2026 | N-PORT |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0,12% | 165.000 | 1. Oktober 2026 | Täglich |
| ROUS · Lattice Strategies Trust | 0,12% | 3.633 NS | 31. Juli 2026 | N-PORT |
| SPMO · Invesco Exchange-Traded Fund Trust … | 0,12% | 115.349 SH | 5. Oktober 2026 | Täglich |
| EVUS · iShares Trust | 0,11% | 1.865 SH | 11. September 2026 | Täglich |
| VIG · VANGUARD SPECIALIZED FUNDS | 0,10% | 625.384 SH | 19. August 2026 | Täglich |
| VYM · VANGUARD WHITEHALL FUNDS | 0,10% | 440.583 SH | 19. August 2026 | Täglich |
| DGRO · iShares Trust | 0,10% | 179.879 SH | 11. September 2026 | Täglich |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,09% | 3.271 SH | 5. Oktober 2026 | Täglich |
| PFM · Invesco Exchange-Traded Fund Trust | 0,09% | 3.153 SH | 5. Oktober 2026 | Täglich |
| VTV · VANGUARD INDEX FUNDS | 0,09% | 1.051.572 SH | 19. August 2026 | Täglich |
| DXUV · Dimensional ETF Trust | 0,09% | 2.092 NS | 31. Juli 2026 | N-PORT |
| CRBN · iShares Trust | 0,09% | 4.406 SH | 11. September 2026 | Täglich |
| DCOR · Dimensional ETF Trust | 0,09% | 12.279 NS | 31. Juli 2026 | N-PORT |
| IVE · iShares Trust | 0,09% | 183.297 SH | 11. September 2026 | Täglich |
| IUSV · iShares Trust | 0,08% | 97.344 SH | 11. September 2026 | Täglich |
| DFAC · Dimensional ETF Trust | 0,08% | 167.227 NS | 31. Juli 2026 | N-PORT |
| VOOV · VANGUARD ADMIRAL FUNDS | 0,08% | 25.423 SH | 19. August 2026 | Täglich |
| CHRI · Global X Funds | 0,08% | 27 NS | 31. Juli 2026 | N-PORT |
| IQSU · New York Life Investments ETF Trust | 0,08% | 1.095 NS | 31. Juli 2026 | N-PORT |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0,08% | 3.155 SH | 5. Oktober 2026 | Täglich |
| SUSL · iShares Trust | 0,08% | 3.907 SH | 11. September 2026 | Täglich |
| ILCV · iShares Trust | 0,07% | 4.337 SH | 11. September 2026 | Täglich |
| DSI · iShares Trust | 0,07% | 16.854 SH | 11. September 2026 | Täglich |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,07% | 66.643 SH | 19. August 2026 | Täglich |
| IWD · iShares Trust | 0,07% | 245.078 SH | 11. September 2026 | Täglich |
| HDUS · Lattice Strategies Trust | 0,07% | 586 NS | 31. Juli 2026 | N-PORT |
| EGLE · Global X Funds | 0,06% | 6 NS | 31. Juli 2026 | N-PORT |
| GLBL · Pacer Funds Trust | 0,06% | 3 NS | 31. Juli 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0,06% | 24.840 SH | 5. Oktober 2026 | Täglich |
| RWL · Invesco Exchange-Traded Fund Trust … | 0,06% | 24.539 SH | 5. Oktober 2026 | Täglich |
| DFSU · Dimensional ETF Trust | 0,05% | 5.056 NS | 31. Juli 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,05% | 26.447 NS | 31. Juli 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,05% | 9.857 SH | 5. Oktober 2026 | Täglich |
| TOPC · iShares Trust | 0,05% | 68 SH | 11. September 2026 | Täglich |
| XVV · iShares Trust | 0,04% | 1.285 SH | 11. September 2026 | Täglich |
| XYLD · Global X Funds | 0,04% | 6.096 NS | 31. Juli 2026 | N-PORT |
| QVML · Invesco Exchange-Traded Fund Trust … | 0,04% | 3.131 SH | 5. Oktober 2026 | Täglich |
| BKLC · BNY Mellon ETF Trust | 0,04% | 9.574 NS | 31. Juli 2026 | N-PORT |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,04% | 15.319 NS | 31. Juli 2026 | N-PORT |
| VOO · VANGUARD INDEX FUNDS | 0,04% | 2.875.103 SH | 19. August 2026 | Täglich |
| VV · VANGUARD INDEX FUNDS | 0,04% | 129.285 SH | 19. August 2026 | Täglich |
| ESGV · VANGUARD WORLD FUND | 0,04% | 24.972 SH | 19. August 2026 | Täglich |
| TOV · EA Series Trust | 0,04% | 426 NS | 31. Juli 2026 | N-PORT |
| PTLC · Pacer Funds Trust | 0,04% | 5.593 NS | 31. Juli 2026 | N-PORT |
| VOTE · TCW ETF Trust | 0,04% | 1.876 NS | 31. Juli 2026 | N-PORT |
| XYLG · Global X Funds | 0,04% | 109 NS | 31. Juli 2026 | N-PORT |
| PBP · Invesco Exchange-Traded Fund Trust | 0,04% | 655 SH | 5. Oktober 2026 | Täglich |
| XCLR · Global X Funds | 0,04% | 6 NS | 31. Juli 2026 | N-PORT |
| IVV · iShares Trust | 0,04% | 1.392.389 SH | 11. September 2026 | Täglich |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0,04% | 17.947 SH | 5. Oktober 2026 | Täglich |
| XTR · Global X Funds | 0,04% | 8 NS | 31. Juli 2026 | N-PORT |
| ILCB · iShares Trust | 0,04% | 2.144 SH | 11. September 2026 | Täglich |
| XRMI · Global X Funds | 0,04% | 82 NS | 31. Juli 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,04% | 33.588 NS | 31. Juli 2026 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0,04% | 417 NS | 31. Juli 2026 | N-PORT |
| QDPL · Pacer Funds Trust | 0,04% | 2.663 NS | 31. Juli 2026 | N-PORT |
| IWB · iShares Trust | 0,04% | 76.198 SH | 11. September 2026 | Täglich |
| VOXP · Advisors Series Trust | 0,04% | 9 NS | 31. Juli 2026 | N-PORT |
| IYY · iShares Trust | 0,04% | 4.688 SH | 11. September 2026 | Täglich |
| IWV · iShares Trust | 0,03% | 30.298 SH | 11. September 2026 | Täglich |
| ITOT · iShares Trust | 0,03% | 141.099 SH | 11. September 2026 | Täglich |
| PHDG · Invesco Actively Managed Exchange-T… | 0,03% | 88 SH | 5. Oktober 2026 | Täglich |
| HCMT · Direxion Shares ETF Trust | 0,03% | 772 NS | 31. Juli 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,03% | 3.515.122 SH | 19. August 2026 | Täglich |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,03% | 18.213 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,03% | 9.300 SH | 19. August 2026 | Täglich |
| SPXL · Direxion Shares ETF Trust | 0,03% | 8.650 NS | 31. Juli 2026 | N-PORT |
| URTH · iShares, Inc. | 0,03% | 10.177 SH | 11. September 2026 | Täglich |
| TILT · FlexShares Trust | 0,03% | 2.686 NS | 31. Juli 2026 | N-PORT |
| TOK · iShares Trust | 0,03% | 292 SH | 11. September 2026 | Täglich |
| ACWI · iShares Trust | 0,03% | 36.161 SH | 11. September 2026 | Täglich |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,02% | 95.097 SH | 19. August 2026 | Täglich |
| DYNF · BlackRock ETF Trust | 0,02% | 34.844 SH | 11. September 2026 | Täglich |
| GTO · Invesco Actively Managed Exchange-T… | 0,00% | 1.000 | 30. September 2026 | Täglich |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | 15. Juli 2026 | Täglich |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | 15. Juli 2026 | Täglich |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 15. Juli 2026 | Täglich |
| VCRB · VANGUARD MALVERN FUNDS | · | · | 15. Juli 2026 | Täglich |
| VSDB · VANGUARD MALVERN FUNDS | · | · | 15. Juli 2026 | Täglich |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | 15. Juli 2026 | Täglich |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | 15. Juli 2026 | Täglich |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | 15. Juli 2026 | Täglich |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | 30. Juli 2026 | Täglich |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 30. Juli 2026 | Täglich |
| VCEB · VANGUARD WORLD FUND | · | · | 30. Juli 2026 | Täglich |
DGX Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
12-Monats-Kursziel
15 Analysten · 2026-10-04Mittelwert-Ziel $247.73 +8,5%
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| DGX | $19.09B | 19.8 | 11.8% | 9.0% | 14.2% | · |
| CVS | $100.87B | 57.1 | 7.8% | 0.44% | 2.4% | · |
| CI | $72.51B | 12.4 | 11.2% | 2.2% | 14.4% | · |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| GH | $13.34B | -30.8 | 32.9% | -42.4% | 205.7% | · |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| BTSG | $7.20B | 43.0 | 28.2% | 1.5% | 10.8% | 11.8% |
| DVA | $7.79B | 11.5 | 6.5% | 5.5% | -281.8% | · |
| HNGE | $0 | -6.0 | 50.6% | -89.9% | -299.8% | 79.7% |
| HIMS | · | 63.7 | 59.0% | 5.5% | 23.3% | 73.8% |
| CHE | · | 23.3 | 4.1% | 10.5% | 24.4% | · |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.